| Overview |
| bs-15583R-PE-Cy5.5 |
| TEM8 Polyclonal Antibody, PE-Cy5.5 Conjugated |
| WB |
| Human, Mouse |
| Rat, Rabbit |
| Specifications |
| PE-Cy5.5 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human TEM8 |
| 201-300/564 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 84168 |
| Q9H6X2 |
| Cell membrane |
| Anthrax toxin receptor 1; Anthrax toxin receptor 1 precursor; ANTXR 1; ANTXR1; ATR; TEM-8; TEM 8; TEM8; Tumor Endothelial Marker 8; Tumor endothelial marker 8 precursor; ANTR1_HUMAN; Anthrax toxin receptor-1; FLJ11298; FLJ21776. |
| This gene encodes a type I transmembrane protein and is a tumor-specific endothelial marker that has been implicated in colorectal cancer. The encoded protein has been shown to also be a docking protein or receptor for Bacillus anthracis toxin, the causative agent of the disease, anthrax. The binding of the protective antigen (PA) component, of the tripartite anthrax toxin, to this receptor protein mediates delivery of toxin components to the cytosol of cells. Once inside the cell, the other two components of anthrax toxin, edema factor (EF) and lethal factor (LF) disrupt normal cellular processes. Three alternatively spliced variants that encode different protein isoforms have been described. [provided by RefSeq, Oct 2008] |
| Application Dilution |
| WB |
1:300-5000 |
Powered by Bioz